title: Ferrous sulfate (Fe2+) had a faster effect than did ferric polymaltose (Fe3+) on increased oxidant status in children with iron-deficiency anemia.
abstract: OBJECTIVE
  The purpose of this study was to compare the total oxidant and antioxidant effect of different oral iron preparations in children with iron-deficiency anemia (IDA).
  
  
  METHODS
  A total of 65 children with IDA were randomized to receive 5 mg Fe/kg/d iron (II) sulfate (Fe(2+) group, n=33) or iron (III)-hydroxide polymaltose complex (Fe(3+) group, n=32); healthy controls (n=28) were also included in the study. Serum total thiol (-SH), total antioxidant capacity (TAC), total oxidant status (TOS), oxidative stress index (OSI), and hematological profile were evaluated at the baseline and on day 8 and day 30 of the therapy.
  
  
  RESULTS
  Serum TOS and OSI levels were significantly higher and total -SH and total antioxidant capacity levels were significantly lower in the study groups at the beginning of therapy than in the controls (P>0.001). In multivariate analysis, after controlling for multiple confounding factors, on days 8 and 30, serum TOS and OSI levels were not different in the Fe(3+) group, whereas they were significantly reduced in the Fe(2+) group (P≤0.033).
  
  
  CONCLUSIONS
  Serum total oxidant status was significantly increased in children with IDA, and Fe(2+) was highly effective in correcting elevated oxidative status.
authors.affiliation: Departments of *Pediatric Hematology ‡Clinical Biochemistry §Pediatrics, Harran University Medical Faculty, Sanliurfa †Department of Pediatric Hematology, Marmara University Medical Faculty, Istanbul, Turkey.
authors.forename: Ali
authors.initials: A
authors.lastname: Aycicek
authors.forename: Ahmet
authors.initials: A
authors.lastname: Koc
authors.forename: Yesim
authors.initials: Y
authors.lastname: Oymak
authors.forename: Sahbettin
authors.initials: S
authors.lastname: Selek
authors.forename: Cemil
authors.initials: C
authors.lastname: Kaya
authors.forename: Bulent
authors.initials: B
authors.lastname: Guzel
mesh_terms: D018798:Anemia, Iron-Deficiency / Q000188:drug therapy*; D000975:Antioxidants / Q000008:administration & dosage*; D002648:Child; D002675:Child, Preschool; D003692:Delayed-Action Preparations / Q000008:administration & dosage; D005260:Female; D005290:Ferric Compounds / Q000008:administration & dosage*; D005296:Ferrous Compounds / Q000008:administration & dosage*; D006397:Hematinics / Q000008:administration & dosage*; D006801:Humans; D008297:Male; D016877:Oxidants / Q000008:administration & dosage*; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects; D016896:Treatment Outcome
chemical_list: D000975:Antioxidants; D003692:Delayed-Action Preparations; D005290:Ferric Compounds; D005296:Ferrous Compounds; D006397:Hematinics; D016877:Oxidants; C020748:ferrous sulfate; C013276:teferrol